echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Medical News > Medical Science News > Merck's Bavencio meets mid-term analysis of bladder cancer

    Merck's Bavencio meets mid-term analysis of bladder cancer

    • Last Update: 2021-03-03
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com
    New data from the JAVELIN Bladder 100 Phase III study show that bavencio (avelumab) reached the primary endpoint of its overall survival rate (overall survival) in the planned midterm analysis, which was previously untreated for locally advanced or metastatic urethra cancer (UC).
    Merck revealed that the drug showed a statistically significant improvement in overall survival in each common primary population: all random groups of patients and patients with PD-L1-positive tumors.
    In addition to the successful results, the safety of human anti-PD-L1 antibodies in this trial is consistent with that of JAVELIN's single-drug clinical development program.
    Currently, combined chemotherapy is the standard of first-line treatment for patients with advanced diseases, but unfortunately, complete remission after first-line chemotherapy is not common, with most patients experiencing disease progression within nine months of the start of treatment.
    Last year, the drug disappointed in the JAVELIN Gastric 100 Phase III study, which evaluated Bavencio's role in localized late-stage or metastasis HER2-negative gastric or gastroesoesic junction (GEJ) cancer.
    Chris Boshoff, Pfizer's chief development officer for oncology, said the drug was "the first immunotherapy to demonstrate in clinical trials that its overall survival rate as a first-line treatment for patients with advanced urethroid skin cancer has improved significantly statistically."latest positive data from the JAVELIN Clinical Development Program provide evidence for Bavencio's treatment of genitourinary cancer, and we look forward to discussing these results with health authorities," he continued. The
    UC accounts for about 90 percent of all bladder cancer and has a five-year survival rate of only 5 percent at the time of metastasis. With the development of subtypes, subtypes become more and more difficult to treat and spread to all layers of the bladder wall, which means that there is an urgent need for other treatment options that can improve overall survival. (cyy123.com)
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.